CASC3 and plasma cell myeloma: In contrast to the anticipated BTZ-induced upregulation of IκBα, evidence in plasma cell myeloma cell lines and primary cells from patients suggests that BTZ could also significantly downregulate IκBα expression, which subsequently triggers NF-κB activation [64].